source
- Researchers urge FDA to adopt EMA-style drug rejection letter disclosuresThe FDA began publishing letters that explain why a drug application was denied in September 2025, marking a significant transparency shift. Researchers argue that the agency’s current disclosures…
- NodThera rebrands as Rezera and targets Phase 3 trial in 2027NodThera, a biotech focused on the NLRP3 inflammatory pathway for about ten years, announced a strategic shift. The company said it will rebrand itself as Rezera and is preparing to launch a pivot…